PMV Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
PMV Pharmaceuticals's earnings have been declining at an average annual rate of -27.1%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-27.1%
Earnings growth rate
47.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -30.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Apr 20
Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Dec 22We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth
Sep 08Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
May 10PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
Jan 11Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Sep 22PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04
Aug 09PMV Pharma joins Merck to study lead candidate with Keytruda
Jul 18Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Jun 09Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Feb 23Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Nov 05Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Jul 23PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business
Apr 09Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?
Dec 25PMV Pharmaceuticals reports Q3 results
Nov 13Revenue & Expenses BreakdownBeta
How PMV Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -69 | 24 | 56 |
| 30 Sep 23 | 0 | -73 | 25 | 58 |
| 30 Jun 23 | 0 | -74 | 25 | 58 |
| 31 Mar 23 | 0 | -74 | 25 | 55 |
| 31 Dec 22 | 0 | -73 | 25 | 52 |
| 30 Sep 22 | 0 | -72 | 25 | 49 |
| 30 Jun 22 | 0 | -69 | 25 | 45 |
| 31 Mar 22 | 0 | -65 | 24 | 41 |
| 31 Dec 21 | 0 | -58 | 22 | 36 |
| 30 Sep 21 | 0 | -50 | 20 | 31 |
| 30 Jun 21 | 0 | -44 | 17 | 27 |
| 31 Mar 21 | 0 | -39 | 13 | 25 |
| 31 Dec 20 | 0 | -34 | 11 | 24 |
| 30 Sep 20 | 0 | -31 | 8 | 23 |
| 30 Jun 20 | 0 | -28 | 7 | 22 |
| 31 Mar 20 | 0 | -27 | 6 | 22 |
| 31 Dec 19 | 0 | -25 | 6 | 21 |
Quality Earnings: PMVP is currently unprofitable.
Growing Profit Margin: PMVP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PMVP is unprofitable, and losses have increased over the past 5 years at a rate of 27.1% per year.
Accelerating Growth: Unable to compare PMVP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PMVP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: PMVP has a negative Return on Equity (-30.56%), as it is currently unprofitable.